Report dose-to-medium in clinical trials where available; A consensus from the Global Harmonisation Group to maximize consistency

Authors

Stephen F Kry, The University of Texas MD Anderson Cancer Center
Jeff Michalski, Washington University School of Medicine in St. Louis
et al.

Journal

Radiotherapy and Oncology

Publication Date

6-1-2021

Volume

159

First Page

106

Last Page

111

Document Type

Open Access Publication

DOI

10.1016/j.radonc.2021.03.006

Rights and Permissions

Kry SF, Lye J, Clark CH, Andratschke N, Dimitriadis A, Followill D, Howell R, Hussein M, Ishikawa M, Kito S, Kron T, Lee J, Michalski J, Filippo Monti A, Reynaert N, Taylor P, Venables K, Xiao Y, Lehmann J. Report dose-to-medium in clinical trials where available; a consensus from the Global Harmonisation Group to maximize consistency. Radiother Oncol. 2021 Jun;159:106-111. doi: 10.1016/j.radonc.2021.03.006 Copyright 2021 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).

Recommended Citation

Kry, Stephen F; Michalski, Jeff; and et al., "Report dose-to-medium in clinical trials where available; A consensus from the Global Harmonisation Group to maximize consistency." Radiotherapy and Oncology. 159, 106 - 111. (2021).
https://digitalcommons.wustl.edu/oa_4/636